Last $58.27 USD
Change Today +0.53 / 0.92%
Volume 3.7M
CFN On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 4:04 PM 11/20/14 All times are local (Market data is delayed by at least 15 minutes).

carefusion corp (CFN) Snapshot

Open
$57.67
Previous Close
$57.74
Day High
$58.29
Day Low
$57.67
52 Week High
11/20/14 - $58.29
52 Week Low
12/17/13 - $37.60
Market Cap
11.9B
Average Volume 10 Days
2.2M
EPS TTM
$2.14
Shares Outstanding
203.9M
EX-Date
--
P/E TM
27.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for CAREFUSION CORP (CFN)

carefusion corp (CFN) Related Businessweek News

View More BusinessWeek News

carefusion corp (CFN) Details

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, and respiratory care. The company operates through two segments, Medical Systems and Procedural Solutions. Its primary product brands include Alaris intravenous (IV) infusion systems; Pyxis and Rowa automated medication dispensing and supply management systems; AVEA, Vela, and LTV Series respiratory ventilators; ChloraPrep skin antiseptic products; MaxGuard, MaxPlus, MaxZero, SmartSite, and Texium needle-free IV infusion valves, and administration sets and accessories; PleurX, Achieve, and Temno interventional specialty products; V. Mueller and Snowden-Pencer open surgical and laparoscopic instrumentation; AirLife disposable ventilator circuits and oxygen masks used for providing respiratory therapy; Jaeger and SensorMedics cardiopulmonary diagnostic equipment; Vital Signs single-use consumables for respiratory care and anesthesiology; and MedMined data mining surveillance software and analytics tools to help hospitals identify adverse drug events and healthcare associated infections. The company also offers CareFusion branded ventilation system; and Guardrails, a software application. Its primary customers include hospitals, ambulatory surgical centers, clinics, long-term care facilities, and physician offices in the United States. The company also sells its products to hospitals in approximately 130 countries. It offers its products directly to group purchasing organizations, as well as through integrated delivery networks, wholesalers, and distributors. CareFusion Corporation was incorporated in 2009 and is headquartered in San Diego, California.

16,000 Employees
Last Reported Date: 08/11/14
Founded in 2009

carefusion corp (CFN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.2M
Chief Financial Officer
Total Annual Compensation: $559.6K
President of Medical Systems
Total Annual Compensation: $498.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $492.9K
Executive Vice President of EMEA/ANZ Commerci...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2014.

carefusion corp (CFN) Key Developments

CareFusion Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014; Reaffirms Earnings Guidance for the Fiscal Year Ending June 30, 2015

CareFusion Corporation reported unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the quarter, the company reported revenue of $922 million, compared to $830 million in the first quarter of fiscal year 2014, an 11% increase on both a reported and constant currency basis. Contributions from the Vital Signs acquisition, continued momentum in the Dispensing Technologies business line, and gains across the Procedural Solutions segment led to strong top-line growth during the quarter. Operating income was $126 million, up 9% from $116 million in the prior year period. Excluding nonrecurring items, adjusted operating income increased 17% to $166 million. The company reported net income of $76 million, or $0.37 per diluted share. Adjusted net income increased 8% from the prior year period to $104 million, or $0.50 per diluted share. Income before income tax was $98 million compared to $96 million in the prior year period. Net income was $76 million or $0.37 per diluted share compared to $78 million or $0.36 per diluted share in the prior year period. Net cash provided by operating activities was $68 million compared to $74 million reported a year ago. Additions to property and equipment were $21 million compared to $18 million reported a year ago. For the fiscal year ending June 30, 2015, the company continues to expect revenue to grow 5 to 7% on a constant currency basis compared to fiscal 2014 revenue of $3.84 billion. The company settled a previously disclosed tax audit with the Internal Revenue Service that will result in a tax rate range of 20 to 22% for the full fiscal year. The tax settlement will have a positive impact on adjusted, diluted EPS in the second quarter, which will be partially offset for the year by an increased diluted weighted average outstanding share count of approximately 208 million, reflecting the suspension of the company's share buyback program as a result of the proposed merger with BD. As a result, adjusted diluted EPS from continuing operations are expected to increase to a range of $2.80 to $2.95 for fiscal 2015, driven primarily by a second quarter tax settlement with the internal revenue service. The company expects GAAP EPS to be in the range of $2.17 to $2.32.

CareFusion Corporation Appoints Supratim Bose to the Board of Governance and Compliance Committee

CareFusion Corporation announced that Mr. Supratim Bose was appointed to serve as a member of the Governance and Compliance Committee of the Board.

Andrews & Springer LLC Files Class Action Lawsuit Against CareFusion Corporation

Andrews & Springer LLC announced that a class action lawsuit has been filed on behalf of stockholders of CareFusion Corporation seeking to challenge the company's recently announced merger. On October 5, 2014, CareFusion and Becton Dickinson & Company announced the signing of a definitive merger agreement pursuant to which Becton will acquire CareFusion in a merger worth $12.2 billion. As a result of the merger, CareFusion shareholders are only anticipated to receive a total of $58.00 per share ($49.00 per share in cash and 0.0777 of a share of Becton) in exchange for each share of CareFusion. Indeed, the announcement of the merger was uniquely timed after CareFusion hit its 52-week high October 3, 2014. Additionally, following the merger, CareFusion shareholders are expected to be substantially diluted, owning only 8% of the combined company. The 0.0777 exchange ratio restricts the value that CareFusion shareholders are expected to receive by exposing CareFusion shareholders to the volatility of Becton's share price. On October 8, 2014, a CareFusion shareholder represented by another law firm filed a class action complaint that challenges the company's merger with Becton. The complaint was filed in the Delaware Court of Chancery, Case No. 10214.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFN:US $58.27 USD +0.53

CFN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $167.11 USD +0.44
Endo International PLC $69.76 USD +0.75
Hospira Inc $58.53 USD -0.28
Terumo Corp ¥2,684 JPY -3.00
Varian Medical Systems Inc $87.88 USD +0.22
View Industry Companies
 

Industry Analysis

CFN

Industry Average

Valuation CFN Industry Range
Price/Earnings 29.3x
Price/Sales 3.0x
Price/Book 2.2x
Price/Cash Flow 28.4x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAREFUSION CORP, please visit www.carefusion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.